Current status of treatment for 2019 novel coronavirus pneumonia
10.3760/cma.j.issn.0254-5101.2020.01.002
- VernacularTitle: 2019新型冠状病毒肺炎治疗研究现状
- Author:
Naiwei ZHU
1
;
Ping ZHAO
;
Zhongtian QI
Author Information
1. Department of Biomedical Defense, PLA Key Laboratory of Biodetection and Biodefense, Shanghai Key Laboratory of Medical Biodefense, Naval Medical University, Shanghai 200433, China
- Publication Type:Journal Article
- Keywords:
2019 novel coronavirus;
Treatment;
Drugs
- From:
Chinese Journal of Microbiology and Immunology
2020;40(1):7-10
- CountryChina
- Language:Chinese
-
Abstract:
2019 novel coronavirus (2019-nCoV) is a new member of coronavirus family that can cause serious respiratory diseases after the emergence of severe acute respiratory syndrome-coronavirus (SARS-CoV) and middle east respiratory syndrome-coronavirus (MERS-CoV). At present, there is no specific antiviral drug targeting 2019-nCoV. In facing of the increasingly serious epidemic of 2019-nCoV pneumonia and the urgent needs in drug treatment strategies, this paper reviewed the current research situation and progress in antiviral treatment for the newly identified disease.
